• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract: Isatuximab improves progression-free survival in patients receiving carfilzomib–dexamethasone treatment for multiple myeloma

byMinjee Kim
July 15, 2021
in StudyGraphics
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

RELATED REPORTS

#VisualAbstract: Addition of elotuzumab to lenalidomide and dexamethasone did not significantly improve survival outcomes in newly diagnosed, transplant-ineligible multiple myeloma

#VisualAbstract: Daratumumab-based therapies were associated with higher rates of sustained minimal residual disease negativity in patients with newly diagnosed multiple myeloma

#VisualAbstract: Melflufen plus dexamethasone showed superior progression-free survival over standard of care in multiple myeloma refractory to lenalidomide

1. Higher rates of treatment response were observed in patients receiving isatuximab with carfilzomib–dexamethasone than carfilzomib–dexamethasone alone.

2. Improved median progression-free survival and estimated survival rates two years after randomization in favor of the isatuximab group.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Multiple myeloma (MM) remains an incurable hematologic malignancy, typically treated with immunomodulators and targeted therapies. Isatuximab is an IgG1 anti-CD38 monoclonal antibody which has shown efficacy in treating multiple myeloma when given in combination with dexamethasone and several immunomodulatory agents. The IKEMA randomized, phase 3, open-label, multicenter clinical trial evaluated the benefit of adding isatuximab to carfilzomib–dexamethasone treatment regiments for refractory multiple myeloma. The primary efficacy outcome was progression-free survival from time of randomization; secondary endpoints included treatment response rate, overall survival, and minimal residual disease (MDR) levels as measured using next-generation sequencing. The results of this study demonstrated higher rates of progression-free survival when isatuximab was added to carfilzomib–dexamethasone treatment regimen. Additionally, the MDR negative rates were twice as high in the isatuximab group than in the carfilzomib–dexamethasone only group. Likewise, overall treatment response improved in the isatuximab group compared to the carfilzomib–dexamethasone only group. However, addition of isatuximab was associated with higher rates of serious treatment-emergent adverse events (TEAEs) compared to carfilzomib–dexamethasone only, resulting in treatment discontinuation for a subset of patients. In particular, the rates of upper respiratory infections, pneumonia, and bronchitis were more common in the isatuximab group.

Click to read the study in The Lancet

Relevant Reading: Isatuximab plus carfilzomib/dexamethasone versus carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma: IKEMA Phase III study design

In-Depth [randomized controlled trial]: This study included 302 patients from 69 international centers. Participants were randomly assigned in a 3:2 ratio to the isatuximab plus carfilzomib–dexamethasone and carfilzomib–dexamethasone control groups, respectively. Participant demographics were comparable between groups. Multiple myeloma subtype, cytogenetic status, and staging at time of randomization were documented at the time of study entry. At the median follow-up time point of 20.7 months, the isatuximab group demonstrated statistically significant improvement in progression-free survival compared to control (HR 0.53, 99% CI [0.32–0.89], one-sided p=0.0007). The estimated rate of progression-free survival at 2 years was 68·9% (95% CI [60.7–75.8]) in the isatuximab group, compared to 45.7% [35.2–55.6] in the control group. The strength of treatment response was significant for the subcategories “very good partial response” or better. The MDR negativity rate was 30% in the isatuximab group versus 13% in the control group (p=0.0004). In terms of treatment-emergent adverse events (TEAEs), both groups had comparable overall rates of TEAEs. However, the isatuximab group demonstrated higher rates of serious TEAEs (grade 3 or worse), most commonly infusion-related infections, cardiac complications, and thromboembolic events. The results of this study are limited by the open-label nature of the trial, which may have biased outcomes. Additionally, Black or African American patients constituted only 3% of the trial cohort. Despite these limitations, the results of this trial support the addition of isatuximab to carfilzomib–dexamethasone treatment regiments, improving survival and treatment efficacy in patients with relapsed multiple myeloma.

Image: PD

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: #carfilzomib–dexamethasone#IKEMAisatuximabMMmultiple myeloma
Previous Post

#VisualAbstract: Pembrolizumab plus cetuximab shows early clinical efficacy for patients with recurrent or metastatic head and neck squamous cell carcinoma

Next Post

#VisualAbstract: Improved sleep quality reduced cardio-metabolic risk factors

RelatedReports

#VisualAbstract: Addition of elotuzumab to lenalidomide and dexamethasone did not significantly improve survival outcomes in newly diagnosed, transplant-ineligible multiple myeloma
StudyGraphics

#VisualAbstract: Addition of elotuzumab to lenalidomide and dexamethasone did not significantly improve survival outcomes in newly diagnosed, transplant-ineligible multiple myeloma

May 19, 2022
#VisualAbstract: Daratumumab-based therapies were associated with higher rates of sustained minimal residual disease negativity in patients with newly diagnosed multiple myeloma
StudyGraphics

#VisualAbstract: Daratumumab-based therapies were associated with higher rates of sustained minimal residual disease negativity in patients with newly diagnosed multiple myeloma

February 3, 2022
#VisualAbstract: Melflufen plus dexamethasone showed superior progression-free survival over standard of care in multiple myeloma refractory to lenalidomide
StudyGraphics

#VisualAbstract: Melflufen plus dexamethasone showed superior progression-free survival over standard of care in multiple myeloma refractory to lenalidomide

January 27, 2022
#VisualAbstract An ixazomib-based regimen may be a better-tolerated approach in elderly patients with newly diagnosed multiple myeloma
StudyGraphics

#VisualAbstract An ixazomib-based regimen may be a better-tolerated approach in elderly patients with newly diagnosed multiple myeloma

December 18, 2021
Next Post
#VisualAbstract: Improved sleep quality reduced cardio-metabolic risk factors

#VisualAbstract: Improved sleep quality reduced cardio-metabolic risk factors

#VisualAbstract: Systematic analysis of tobacco smoking prevalence in 204 countries from 1990 to 2019

#VisualAbstract: Systematic analysis of tobacco smoking prevalence in 204 countries from 1990 to 2019

Exercise intervention linked to reduced functional decline among elderly patients admitted to the hospital

Wellness Check: Mental Health

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Risk of post-vitrectomy endophthalmitis may have increased during the COVID-19 pandemic
  • Bosniak classification system differentiates benign renal cysts from cystic carcinoma [Classics Series]
  • Cognitive behavioral therapy efficacious for treatment of comorbid posttraumatic headache and posttraumatic stress disorder symptoms among US veterans
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.